0001209191-20-051614.txt : 20200922
0001209191-20-051614.hdr.sgml : 20200922
20200922212003
ACCESSION NUMBER: 0001209191-20-051614
CONFORMED SUBMISSION TYPE: 4
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20200918
FILED AS OF DATE: 20200922
DATE AS OF CHANGE: 20200922
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: Rosenberg Noah L.
CENTRAL INDEX KEY: 0001579649
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 001-36257
FILM NUMBER: 201190816
MAIL ADDRESS:
STREET 1: C/O ESPERION THERAPEUTICS, INC.
STREET 2: 46701 COMMERCE CENTER DRIVE
CITY: PLYMOUTH
STATE: MI
ZIP: 48170
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: Retrophin, Inc.
CENTRAL INDEX KEY: 0001438533
STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834]
IRS NUMBER: 262383102
STATE OF INCORPORATION: DE
FISCAL YEAR END: 1231
BUSINESS ADDRESS:
STREET 1: 3721 VALLEY CENTRE DR.
STREET 2: SUITE 200
CITY: SAN DIEGO
STATE: CA
ZIP: 92130
BUSINESS PHONE: 760-260-8600
MAIL ADDRESS:
STREET 1: 3721 VALLEY CENTRE DR.
STREET 2: SUITE 200
CITY: SAN DIEGO
STATE: CA
ZIP: 92130
FORMER COMPANY:
FORMER CONFORMED NAME: Desert Gateway, Inc.
DATE OF NAME CHANGE: 20080625
4
1
doc4.xml
FORM 4 SUBMISSION
X0306
4
2020-09-18
0
0001438533
Retrophin, Inc.
RTRX
0001579649
Rosenberg Noah L.
C/O RETROPHIN, INC.
3721 VALLEY CENTRE DRIVE, SUITE 200
SAN DIEGO
CA
92130
0
1
0
0
Chief Medical Officer
Common Stock
2020-09-18
4
A
0
3000
0.00
A
29055
D
Common Stock
2020-09-22
4
S
0
750
18.59
D
28305
D
On May 9, 2019, the reporting person was granted performance restricted stock units (PRSUs) covering 6,000 shares of the Issuer's common stock, which vest upon the satisfaction of certain performance criteria. On September 18, 2020, a portion of the PRSUs vested upon the Issuer's confirmation that the first 280 patients in the sparsentan PROTECT Phase 3 Study had been enrolled.
The sales reported in this Form 4 were made pursuant to a written plan meeting the requirements of Rule 10b5-1(c) of the Securities Exchange Act of 1934, as amended, and includes the sale of shares to cover the tax obligation
that occurred upon the vesting of performance restricted stock units.
/s/ Elizabeth E. Reed, Attorney-in-Fact
2020-09-22